PMID-25038357 – Tesamorelin Reduces Visceral and Liver Fat RCT
Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389.
Quick Reference
| Property | Value |
|---|---|
| PMID | 25038357 |
| DOI | 10.1001/jama.2014.8334 |
| Year | 2014 |
| Journal | JAMA |
| Study Type | RCT |
| Evidence Level | I (Oxford CEBM) |
| Sample | n=50 HIV-infected adults with abdominal fat accumulation |
| Peptide(s) Studied | Tesamorelin |
Key Findings
- Tesamorelin 2 mg/day subcutaneous injection significantly reduced visceral adipose tissue (VAT) compared to placebo over 12 months
- Hepatic fat fraction decreased significantly in tesamorelin-treated patients, demonstrating a beneficial effect on liver steatosis
- Improvements in body composition occurred without significant changes in subcutaneous adipose tissue, indicating selective visceral fat reduction
- Tesamorelin was well-tolerated with an acceptable safety profile in this HIV-positive population
- IGF-1 levels increased appropriately with tesamorelin treatment, confirming GH-axis activation
- This study provided key evidence supporting tesamorelin's role beyond lipodystrophy correction to include hepatic steatosis reduction
Study Design
Randomized, double-blind, placebo-controlled trial. 50 HIV-infected patients with abdominal fat accumulation were randomized to tesamorelin 2 mg/day or placebo via subcutaneous injection for 12 months. Primary endpoints included change in visceral adipose tissue (measured by CT) and hepatic fat fraction (measured by MR spectroscopy). Secondary endpoints included changes in subcutaneous adipose tissue, lipid profiles, and glucose metabolism parameters.
Limitations
- Relatively small sample size (n=50)
- Study population limited to HIV-infected individuals, limiting generalizability to non-HIV populations
- 12-month duration may not capture long-term effects or sustainability of fat reduction after discontinuation
- Single-center study
- Hepatic fat fraction was a secondary endpoint in the original trial design
Clinical Relevance
This study is a landmark RCT demonstrating that tesamorelin selectively reduces visceral and hepatic fat in HIV-associated lipodystrophy. The liver fat reduction finding is particularly important, as it positions tesamorelin as a potential therapeutic option for NAFLD/hepatic steatosis in HIV patients. The selective reduction of visceral fat without significant loss of subcutaneous fat is clinically desirable. Published in JAMA, this high-impact study significantly strengthened the evidence base for tesamorelin's metabolic benefits.
Related
#research #RCT #evidence-level-I #tesamorelin #metabolic